The capacity of MFAEs to activate Keap1/Nrf2 signaling has also been validated in other pathological conditions (for example, alcohol-induced liver damage [19, 42, 43], cardiovascular disease [44], and antioxidant disorders [17, 45, 46]. Here, KEAP1 is linked to cardiovascular disorder.